Adagene Business Summary

Adagene Inc. (ADAG) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of strategic licensing agreements, milestone-based collaborations, and R&D service fees. Its business model leverages a proprietary suite of AI-driven antibody discovery platforms—SAFEbody, NEObody, and POWERbody—to engineer next-generation immunotherapies targeting "intractable" epitopes. The company’s primary segments are divided between its internal clinical pipeline, featuring candidates like the CTLA-4 inhibitor muzastotug (ADG126), and its technology-out-licensing division which serves global partners such as Sanofi and Merck. Within the oncology-focused biotechnology market, Adagene competes directly with Sino Biological, Transcenta, and Alphamab Oncology, positioning itself as a specialized platform innovator that utilizes "masked" antibody technology to enhance the safety and efficacy profiles of traditional checkpoint inhibitors. Adagene was co-founded by Dr. Peter (Peizhi) Luo, who serves as Chairman, CEO, and President of R&D; Dr. Luo previously served as the first lead scientist in computational protein design at Xencor. The leadership team is further anchored by Chief Financial Officer Man Kin (Raymond) Tam, who brings over two decades of financial expertise from J.P. Morgan and HSBC, and Chief Strategy Officer Mickael Chane-Du, who oversees global corporate development. Other key executives include Dr. Jiping Zha, Executive Vice President of Clinical Development, who held senior roles at Genentech and MedImmune, and Dr. Qinghai Zhao, Chief Manufacturing Officer. The company is supported by a notable investor base including Sequoia Capital, WuXi AppTec, and Eight Roads Ventures, with a board of directors that features industry veterans like Li Zhu, the Chief Strategy Officer of GenScript.